PMC:7544934 / 5616-5953
Annnotations
LitCovid_Glycan-Motif-Structure
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T15 | 224-227 | https://glytoucan.org/Structures/Glycans/G00057MO | denotes | LDN |
| T16 | 224-227 | https://glytoucan.org/Structures/Glycans/G31736BK | denotes | LDN |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 157 | 170-178 | Species | denotes | patients | Tax:9606 |
| 161 | 14-22 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 162 | 75-84 | Disease | denotes | infection | MESH:D007239 |
| 163 | 88-96 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 164 | 161-169 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 165 | 320-328 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T42 | 0-337 | Sentence | denotes | As a reliable COVID-19 vaccine is unlikely to available before the maximal infection of COVID-19 has occurred, it is essential to establish therapeutics for the COVID-19 patients, based on our data, we proposed FDA-approved LDN can be used in combination or as an adjuvants therapy to treat mild to moderate symptomatic COVID-19 patients |